Triflorcas impairs in vivo tumor growth of cancer cells carrying oncogenic Met, without causing major side effects.

<p>(A) Evolution of the body weight in mice, treated intra-peritoneally with either vehicle or Triflorcas (TFC; 30 mg.kg⁻¹ every day) showed no significant differences. Body weight is expressed as weight evolution over the 21 day-treatment period. (B) The weight of heart, spleen, kidney, and liver was evaluated in mice daily injected with Triflorcas (30 mg.kg⁻¹) or vehicle for 21 days. No significant differences were observed. Values are expressed as means ± s.e.m. <i>P</i>>0.05. (C and D) Triflorcas treatment (i.p. 30 and 60 mg.kg⁻¹ every other day) reduced tumor volume (C) and weight (D) in nude mice injected sub-cutaneously with H1437 cells. Crizotinib (50 mg.kg⁻¹ daily) did not impair tumor growth. Values are reported as boxplots and expressed as means ± s.e.m. *<i>P</i><0.05; Student-<i>t</i> test.